Vaccines
1 December 2020
HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-1011 December 2020
Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA1 December 2020
BioVaxys Provides Viral Vaccine Platform Program Update1 December 2020
City of Hope COVID-19 Investigational Vaccine Produces Strong Immunity in Preclinical Research26 November 2020
COVAXX Announces $2.8 Billion in Advance Purchase Commitments to Deliver More Than 140 Million Vaccine Doses to Emerging Countries24 November 2020
City of Hope Initiates Phase 1 Clinical Trial to Test Its First SARS-CoV-2 Investigational Vaccine24 November 2020
GSK starts phase 3 study of RSV maternal candidate vaccine23 November 2020
Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine23 November 2020
European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older20 November 2020
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine19 November 2020
VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection19 November 2020
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM18 November 2020
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints18 November 2020
Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases17 November 2020
AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival17 November 2020
European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)17 November 2020
INOVIO announces initiation of Phase 2 segment of Phase 2/3 clinical trial for COVID-19 DNA vaccine candidate INO-480017 November 2020
Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate16 November 2020
Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated TemperaturesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports